Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Background: Successful treatment of major depressive disorder (MDD) can be challenging, and failures ("treatment-resistant depression" [TRD]) are frequent. Steps to address TRD include increasing antidepressant dose, combining antidepressants, adding adjunctive agents, or using nonpharmacological treatments. Their relative efficacy and tolerability remain inadequately tested. In particular, the value and safety of increasingly employed second-generation antipsychotics (SGAs) and new esketamine, compared to lithium as antidepressant adjuncts remain unclear. Methods: We reviewed randomized, placebo-controlled trials and used random-effects meta-analysis to compare odds ratio (OR) versus placebo, as well as numbers-needed-to-treat (NNT) and to-harm (NNH), for adding SGAs, esketamine, or lithium to antidepressants for major depressive episodes. Results: Analyses involved 49 drug-placebo pairs. By NNT, SGAs were more effective than placebo (NNT = 11 [CI: 9–15]); esketamine (7 [5–10]) and lithium (5 [4–10]) were even more effective. Individually, aripiprazole, olanzapine+fluoxetine, risperidone, and ziprasidone all were more effective (all NNT < 10) than quetiapine (NNT = 13), brexpiprazole (16), or cariprazine (16), with overlapping NNT CIs. Risk of adverse effects, as NNH for most-frequently reported effects, among SGAs versus placebo was 5 [4–6] overall, and highest with quetiapine (NNH = 3), lowest with brexpiprazole (19), 5 (4–6) for esketamine, and 9 (5–106) with lithium. The risk/benefit ratio (NNH/NNT) was 1.80 (1.25–10.60) for lithium and much less favorable for esketamine (0.71 [0.60–0.80]) or SGAs (0.45 [0.17–0.77]). Conclusions: Several modern antipsychotics and esketamine appeared to be useful adjuncts to antidepressants for acute major depressive episodes, but lithium was somewhat more effective and better tolerated. Limitations: Most trials of adding lithium involved older, mainly tricyclic, antidepressants, and the dosing of adjunctive treatments were not optimized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Forest plots of random-effects meta-analyses for clinical trials testing the efficacy of supplementing antidepressants with active agents or placebo for major depression: (a) second-generation antipsychotics (SGAs, 28 trials), (b) intranasal esketamine (7 trials), or (c) lithium carbonate (13 trials). SGAs tested were: APZ, aripiprazole; BRX, brexpiprazole; CAR, cariprazine; OFC, olanzapine+fluoxetine combination; QTP, quetiapine; RSP, risperidone; ZPS, ziprasidone. Adding all three types of active treatments were much more effective than adding placebo: (a) SGAs: pooled OR = 1.59 [CI: 1.44–1.75]; z-score = 9.16, p < 0.0001; (b) esketamine: pooled OR = 1.85 [1.45–2.35]; z-score = 4.98, p < 0.0001; Lithium: pooled OR = 2.12 [1.46–3.09]; z = 3.92, p < 0.0001. Heterogeneity ratings (I2) all were <1.0%.](https://figures.cochat.ai/paper-figures/372a930fc9324c15b510a6bb607dd6a6/efficacy-and-tolerability-of-combination-treatments-for-major-depression-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous meta-analyses have shown evidence for the use of AAs, lithium, ketamine and esketamine (Carter et al., 2020; Strawbridge et al., 2019; Vázquez et al., 2021; Zhou et al., 2015).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Vázquez et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meta- analytic data also indicate that glutamatergic treatment strategies may be superior to antipsychotic agents in adults with TRD 200,201 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [201]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, these data provide further evidence of lithium’s antidepressant efficacy which is consistent with the results of a recent meta-analysis (Vázquez et al., 2021).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Vázquez et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“We measured heterogeneity using the I2 statistic (Higgins and Thompson, 2002).”
MethodHamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“Most identified studies defined “response” as at least a 50% reduction in scores with standardized depressive symptom rating-scales, commonly the Hamilton depression rating scale [HDRS17] or MontgomeryÅsberg Depression Rating Scale [MADRS]) (Hamilton, 1960; Montgomery and Åsberg, 1979).”
BackgroundLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 2×
“The PRISMA-guided process of selecting reports for inclusion is summarized in Appendix Figure A1.”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“Most identified studies defined “response” as at least a 50% reduction in scores with standardized depressive symptom rating-scales, commonly the Hamilton depression rating scale [HDRS17] or MontgomeryÅsberg Depression Rating Scale [MADRS]) (Hamilton, 1960; Montgomery and Åsberg, 1979).”
BackgroundFerrari, A. J., Somerville, A. J., Baxter, A. J., Norman, R., Patten, S. B., Vos, T., & Whiteford, H. A. (2013) · Psychological Medicine · doi:10.1017/s0033291712001511 · Cited by 1,230 · cited 6×
“Major depressive disorder (MDD) is a highly prevalent, episodic, or sometimes chronic illness associated with potentially severe functional impairment, co-occurring psychiatric and general medical morbidity, and excess mortality from suicide as well as from general medical conditions (Baldessarini and Tondo, 2020; Cel…”
BackgroundInfluentialKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Treatment-resistant depression: molecular mechanisms and management
Kajumba, M. M., Kakooza‐Mwesige, A., Nakasujja, N., Attix, D. K., & Canli, T. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00205-y · Cited by 106
“…dose optimization, switching, combination, and/or augmentation with other agents, such as atypical antipsychotics [11–14], ketamine [15, 16], lithium [7, 17], Chinese herbal medicine [18, 19], and/or non-pharmacological therapies, like neurostimulation [16, 20], and psycho-therapy [21].”
BackgroundEsketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Understanding the habenula: A major node in circuits regulating emotion and motivation
Ables, J. L., Park, K., & Ibáñez-Tallon, I. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106734 · Cited by 87
Metadata
- Authors
- Vázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J.
- Affiliations
- Queen's University (CA)
- University of Calgary (CA)
- Universidad del Desarrollo (CL)
- Harvard University (US)
- Corresponding author
- Vázquez, Gustavo H.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2021-07-09
- Volume
- 35
- Issue
- 8
- Pages
- 890-900
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC8358538
- OpenAlex
- W3182403469
- Cited by
- 95
- References
- 81
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 21 · 2023: 24 · 2022: 18 · 2021: 3
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (unspecified)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- aretaeus foundation of rome (ANID-PIA-ACT192064)
- Centro Bini Private Donors Research Fund (ANID-FONDECYT 1180358, ANID-FONDECYT 1200601)
- clínica alemana de santiago (ID 863)
- Bruce J. Anderson Foundation
- McLean Private Donors Research Fund
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- major depressive disorder, antidepressant augmentation, atypical antipsychotics, esketamine, lithium, aripiprazole, olanzapine, risperidone, quetiapine, brexpiprazole, cariprazine, ziprasidone, efficacy, tolerability, risk-benefit ratio, adverse effects
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Ketamine, Antipsychotic Agents, Randomized Controlled Trials as Topic, Lithium Compounds, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. https://app.cochat.ai/papers/10.1177/02698811211013579
- The paper
- Vázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2021). Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. Journal of Psychopharmacology. https://doi.org/10.1177/02698811211013579
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.